Lung alveolar epithelial cell (AEC)

Lung alveolar epithelial cells (AECs) are the specialized cells that line the pulmonary alveoli, forming the critical interface for gas exchange between the atmosphere and the bloodstream. They are divided into two primary types: Type I (AT1) cells, which are thin, squamous cells optimized for gas diffusion, and Type II (AT2) cells, which are cuboidal cells responsible for secreting pulmonary surfactant and acting as progenitor cells for alveolar repair (StatPearls, 2023). These cells play a central role in maintaining the air-blood barrier and regulating the lung's innate immune response. In disease states, AEC dysfunction is a hallmark of conditions like Idiopathic Pulmonary Fibrosis (IPF), where impaired AT2 cell regeneration leads to scarring, and Acute Respiratory Distress Syndrome (ARDS), where epithelial damage causes fluid leakage into the airspaces (PubMed, 2021). While AECs are a cellular population rather than a single molecular target, they express key proteins like Angiotensin-Converting Enzyme 2 (ACE2), which serves as the entry point for SARS-CoV-2, and are the primary site of action for inhaled therapies and surfactant replacement (NIH, 2022). Pharmacological interventions often aim to protect these cells from injury or leverage their metabolic functions to restore lung homeostasis.

Other names

PneumocyteAlveolar cellType I alveolar cellType II alveolar cellAlveolar epitheliumAlveolar epithelial cell

Pharmacological agents interact with lung alveolar epithelial cells by binding to specific surface receptors, such as beta-2 adrenergic receptors for bronchodilation, or by replacing deficient endogenous substances like pulmonary surfactant (StatPearls, 2023). Additionally, antifibrotic drugs target intracellular signaling pathways within these cells to prevent the progression of interstitial lung diseases and maintain epithelial integrity (PubMed, 2021).